Actinium Pharmaceuticals Inc. has announced new preclinical data for ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, demonstrating significant anti-tumor activity in hormone receptor positive (HR+), HER2 positive (HER2+), and triple-negative breast cancer (TNBC) models resistant to standard-of-care therapies, including tamoxifen and trastuzumab. The data indicate that ATNM-400 may overcome resistance to both endocrine and HER2-targeted therapies and shows potent tumor growth inhibition in TNBC models. These results are scheduled to be presented at the San Antonio Breast Cancer Symposium on December 11, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY35932) on December 01, 2025, and is solely responsible for the information contained therein.